The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# **FORM D**

#### OMB APPROVAL OMB Number: Estimated average burden hours per response:

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001434316			X Corporation
Name of Issuer			Limited Partnership
FATE THERAPEUTICS INC			Limited Liability Company
Jurisdiction of Incorporation/0	Organization		
DELAWARE			General Partnership
Year of Incorporation/Organiz	ation		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (S	Specify Year)		<del>_</del>
Yet to Be Formed	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Tet to be Folliled			
2. Principal Place of Busine	ss and Contact Information		
Name of Issuer			
FATE THERAPEUTICS INC			
Street Address 1		Street Address 2	
3535 GENERAL ATOMICS CO	OURT	SUITE 200	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92121	858.875.1803
3. Related Persons			
Last Name	First Name		Middle Name
WOLCHKO	J. SCOTT		
Street Address 1	Street Address 2		
C/o Fate Therapeutics, Inc.	3535 General Atom	ics Court, Suite 200	
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92121
Relationship: X Executive C	Officer X Director Promoter		
Clarification of Response (if N	lecessary):		
Last Name	First Name		Middle Name
COUGHLIN	TIMOTHY		P.
Street Address 1	Street Address 2		
C/o Fate Therapeutics, Inc.	3535 General Atom	ics Court, Suite 200	
City	State/Province/Co	ountry	ZIP/PostalCode
San Diego	CALIFORNIA		92121
Relationship: Executive O	officer X Director Promoter		
Clarification of Response (if N	lecessary):		
Last Name	First Name		Middle Name
ENYEDY	MARK		J.
Street Address 1	Street Address 2		<del></del>
C/o Fate Theraneutics Inc		ics Court Suite 200	

City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer	r X Director Promoter	
<u> </u>		
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
EPSTEIN	ROBERT	S.
Street Address 1	Street Address 2	
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 200	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer	r X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
MENDLEIN	JOHN	
Street Address 1	Street Address 2	
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 200	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
<u> </u>		72121
Relationship: Executive Officer	x Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
NASHAT	AMIR	
Street Address 1	Street Address 2	
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 200	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
		) <u></u>
· <u>—</u>	r X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
RASTETTER	WILLIAM	
Street Address 1	Street Address 2	
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 200	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer	r X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
ABBOT	STEWART	
Street Address 1	Street Address 2	
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 200	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: X Executive Office		) Li Li
Clarification of Response (if Neces		
Last Name	First Name	Middle Name
SHOEMAKER	DANIEL	D.
Street Address 1	Street Address 2	

C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 2	200	
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92121	
Relationship: X Executive Officer Direct	ctor Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
TAHL	CINDY		
Street Address 1	Street Address 2		
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 2		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92121	
Relationship: X Executive Officer Direct	ctor Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
STORGARD	CHRIS		
Street Address 1	Street Address 2		
C/o Fate Therapeutics, Inc.	3535 General Atomics Court, Suite 2	200	
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92121	
Relationship: X Executive Officer Direct	ctor Promoter		
Clarification of Response (if Necessary):  4. Industry Group			
Agriculture  Banking & Financial Services  Commercial Banking  Insurance  Investing  Investment Banking  Pooled Investment Fund  Is the issuer registered as an investment company under the Investment Company Act of 1940?  Yes No  Other Banking & Financial Services  Business Services  Energy  Coal Mining  Electric Utilities  Energy Conservation  Environmental Services  Oil & Gas  Other Energy	Health Care  X Biotechnology  Health Insurance  Hospitals & Physicians  Pharmaceuticals  Other Health Care  Manufacturing  Real Estate  Commercial  Construction  REITS & Finance  Residential  Other Real Estate	Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other	
5. Issuer Size			

No Revenues	No Aggregate Net Asset Value				
\$1 - \$1,000,000	\$1 - \$5,000,000				
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000				
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000				
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000				
Over \$100,000,000	Over \$100,000,000				
X Decline to Disclose	Decline to Disclose				
Not Applicable	Not Applicable				
6. Federal Exemption(s) and Exclusion(s) Claimed (s	colont all that apply)				
o. rederal Exemption(s) and Exclusion(s) Claimed (s	егест ан тнаг арргу)				
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Company Act Section 3(c)				
Rule 504 (b)(1)(i)	Section 3(c)(1) Section 3(c)(9)				
Rule 504 (b)(1)(ii)	Section 3(c)(2) Section 3(c)(10)				
Rule 504 (b)(1)(iii)					
Rule 505	<b>-</b>				
X Rule 506(b)	Section 3(c)(4) Section 3(c)(12)				
Rule 506(c)	Section 3(c)(5) Section 3(c)(13)				
Securities Act Section 4(a)(5)	Section 3(c)(6) Section 3(c)(14)				
	Section 3(c)(7)				
L					
7. Type of Filing					
WW N	0.1. V. I 0				
片	Sale Yet to Occur				
Amendment					
8. Duration of Offering					
Done the leaves intend this offering to lock many their section.	veer2 Tyes VNs				
Does the Issuer intend this offering to last more than or	ne year? Yes X No				
9. Type(s) of Securities Offered (select all that apply)					
- ·	Пъ. и и и и				
X Equity	Pooled Investment Fund Interests				
Debt Tenant-in-Common Securities					
Option, Warrant or Other Right to Acquire Another Security  Mineral Property Securities					
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security					
10. Business Combination Transaction					
Is this offering being made in connection with a busines merger, acquisition or exchange offer?	s combination transaction, such as a Yes X No				
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside investi	or \$0 USD				
12. Sales Compensation					
Recipient	Recipient CRD Number X None				
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{X}$ None				
Street Address 1	Street Address 2				
City	State/Province/Country	ZIP/Postal Code			

State(s) of Solicitation (select all that apply) Check "All States" or check individual States  All States  Foreign/non-US
13. Offering and Sales Amounts
Total Offering Amount \$10,290,000 USD or Indefinite
Total Amount Sold \$10,290,000 USD
Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SURMIT below to

#### **Terms of Submission**

file this notice.

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
FATE THERAPEUTICS INC	J. SCOTT WOLCHKO	J. SCOTT WOLCHKO	President and Chief Executive Officer	2016-08-19

# Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.